Targeting the Complement C1 Proteases Using Camelid-Derived Single Domain Antibodies: Production, Characterization and Possible Application for Tissue/Fluid Analysis.
- 1University Grenoble Alpes, CNRS, CEA, IBS, Team CIRDis, F-38000 Grenoble, France.
- 2Centre de Recherche des Cordeliers, Team Inflammation, Complement and Cancer, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, 15 Rue de l'Ecole de Medecine, F-75006 Paris, France.
- 3University Hospital Federation (FHU) COMET, F-75006 Paris, France.
Abstract
Background
The complement C1r and C1s proteases initiate the classical complement pathway within the C1 complex, but emerging evidence points to additional roles in tissues, including cell-intrinsic functions linked to cancer and connective tissue disorders. Few tools are available to explore these plasma and tissue-relevant functions. We report the first development and characterization of anti-C1r and anti-C1s VHH single-domain antibodies (nanobodies).Methods
A lama was immunized with the purified human C1r2/C1s2 tetramer. After phage display selection, two anti-C1r VHHs (C1rCl1, C1rCl6) and one anti-C1s VHH (C1sCl7) were produced in E. coli and characterized by ELISA, Western blot, SPR and size-exclusion chromatography using recombinant protease fragments and proenzyme forms. Functional impact on C1s activation was assessed by cleavage assay, and tissue applicability by immunohistochemistry on human skin sections.Results
All three VHHs bound with high affinity to both active and proenzyme forms. Epitope mapping localized C1rCl1 and C1rCl6 to the CCP2 module of C1r, and C1sCl7 to the CCP1 module of C1s. The two anti-C1r VHHs recognize distinct, non-overlapping epitopes and can bind simultaneously to C1r. C1rCl1 mildly inhibited C1s activation by C1r. The VHH pair C1rCl1/C1rCl6 enabled sandwich ELISA detection of C1r in serum, plasma, and cell culture supernatant. Immunohistochemistry on human skin confirmed clean C1r staining in keratinocytes and fibroblasts, with a dissociated tissue distribution compared to C1s.Conclusions
These first anti-C1r and anti-C1s nanobodies constitute useful tools for detection in biological fluids and tissue staining, with potential applications in diseases where these proteases play a pathological role.
Related
- Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice
- Genomic and biological characterization of three lytic phages targeting Vibrio parahaemolyticus and their application in a raw salmon model
- Dendrimer Delivered shRNA Targeting the CCL20-CCR6 Axis Suppresses Complement-Mediated Microglial Synaptic Pruning and Ameliorates Chronic Neuroinflammation After Repetitive Traumatic Brain Injury
- Cell-intrinsic complement C3 suppresses IFN-β production in macrophages
- Structural basis for broad orthopoxvirus neutralization by two antibodies targeting distinct L1R epitopes
BibTeX
@article{haut2026targeting,
title = {{Targeting the Complement C1 Proteases Using Camelid-Derived Single Domain Antibodies: Production, Characterization and Possible Application for Tissue/Fluid Analysis.}},
author = {Nolwenn Haut and Véronique Rossi and Julie Peliconi and Jean-Baptiste Reiser and Nicole M Thielens and Lubka T Roumenina and Christine Gaboriaud},
journal = {Antibodies (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antib15050092},
url = {https://europepmc.org/article/MED/42930034},
note = {CC BY},
}
RIS
TY - JOUR
TI - Targeting the Complement C1 Proteases Using Camelid-Derived Single Domain Antibodies: Production, Characterization and Possible Application for Tissue/Fluid Analysis.
AU - Nolwenn Haut
AU - Véronique Rossi
AU - Julie Peliconi
AU - Jean-Baptiste Reiser
AU - Nicole M Thielens
AU - Lubka T Roumenina
AU - Christine Gaboriaud
PY - 2026
DA - 2026/10/05
JO - Antibodies (Basel, Switzerland)
DO - 10.3390/antib15050092
UR - https://europepmc.org/article/MED/42930034
AB - Background The complement C1r and C1s proteases initiate the classical complement pathway within the C1 complex, but emerging evidence points to additional roles in tissues, including cell-intrinsic functions linked to cancer and connective tissue disorders. Few tools are available to explore these plasma and tissue-relevant functions. We report the first development and characterization of anti-C1r and anti-C1s VHH single-domain antibodies (nanobodies).Methods A lama was immunized with the purified human C1r2/C1s2 tetramer. After phage display selection, two anti-C1r VHHs (C1rCl1, C1rCl6) and one anti-C1s VHH (C1sCl7) were produced in E. coli and characterized by ELISA, Western blot, SPR and size-exclusion chromatography using recombinant protease fragments and proenzyme forms. Functional impact on C1s activation was assessed by cleavage assay, and tissue applicability by immunohistochemistry on human skin sections.Results All three VHHs bound with high affinity to both active and proenzyme forms. Epitope mapping localized C1rCl1 and C1rCl6 to the CCP2 module of C1r, and C1sCl7 to the CCP1 module of C1s. The two anti-C1r VHHs recognize distinct, non-overlapping epitopes and can bind simultaneously to C1r. C1rCl1 mildly inhibited C1s activation by C1r. The VHH pair C1rCl1/C1rCl6 enabled sandwich ELISA detection of C1r in serum, plasma, and cell culture supernatant. Immunohistochemistry on human skin confirmed clean C1r staining in keratinocytes and fibroblasts, with a dissociated tissue distribution compared to C1s.Conclusions These first anti-C1r and anti-C1s nanobodies constitute useful tools for detection in biological fluids and tissue staining, with potential applications in diseases where these proteases play a pathological role.
SN - 2073-4468
ER -